New drug combo shows promise for advanced cancers in early trial

NCT ID NCT05025085

Completed Disease control Sponsor: Agenus Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 34 times

Summary

This early-phase study tested a new drug called AGEN1777, alone or with another drug (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study is now complete, and results help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Lifespan Cancer Institute

Providence, Rhode Island, 02903, United States
Local Institution - 0001

Providence, Rhode Island, 02903, United States
Local Institution - 024

Southfield, Michigan, 48075, United States
Local Institution - 072

Cincinnati, Ohio, 45267-0558, United States
Local Institution - 164

Dallas, Texas, 75230, United States
Local Institution - 165

Grand Rapids, Michigan, 49546, United States
MD Anderson Cancer Center Thoracic-Head & Neck Med Onc

Houston, Texas, 77030, United States
Mary Crowley Cancer Research

Dallas, Texas, 75251, United States
Providence Cancer Institute

Portland, Oregon, 97213, United States
START Midwest

Grand Rapids, Michigan, 49546, United States
University of Cincinnati Cancer Center

Cincinnati, Ohio, 45267, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED CANCER